Comentarios
Configuración

Configuración

Ir a una solicitud

7.579 resultados
Oficinas all Idiomas es Separación automática de palabras en lexemas true Miembro de una familia de patentes simple false Incluir la LDP false
La fuente RSS solo puede generarse si tiene una cuenta OMPI.

Guardar consulta

Únicamente podrá ver una consulta privada cuando está conectado, y no podrá usarse en fuentes RSS

Arborescencia de consulta

Afinar opciones

Oficinas
Todo
Especificar el idioma de búsqueda de las palabras clave utilizadas
La función "separación automática de palabras en lexemas" sirve para buscar el lexema de las palabras con desinencia.
Por ejemplo, solo se tiene en cuenta el lexema de las palabras fotografiar, fotografiado,fotografía, y fotógrafo, esto es,fotograf
. Así, pues, al buscar fotografiar se encuentran todas las variantes posibles
Generar solamente un miembro de una familia de patentes
Incluir la literatura distinta de la de patentes (LDP) en los resultados

Consulta completa

IC_EX:A61K39/395 AND EN_ALLTXT:(coronavirus OR coronaviruses OR coronaviridae OR coronavirinae OR orthocoronavirus OR orthocoronaviruses OR orthocoronaviridae OR orthocoronavirinae OR betacoronavirus OR betacoronaviruses OR betacoronaviridae OR betacoronavirinae OR sarbecovirus OR sarbecoviruses OR sarbecoviridae OR sarbecovirinae OR "severe acute respiratory syndrome" OR sars OR "2019 ncov" OR covid)

Ver teclas de acceso rápido en dos columnas

General
Ir al espacio Buscar
CTRL + SHIFT +
Ir a Resultados (registro seleccionado)
CTRL + SHIFT +
Ir a Detalle (pestaña seleccionada)
CTRL + SHIFT +
Ir a Página siguiente
CTRL +
Ir a Pagina anterior
CTRL +
Resultados (Primero, "Ir a Resultados")
Ir a Siguiente registro / imagen
/
Ir a Registro o Imagen anterior
/
Desplazar hacia arriba
Page Up
Desplazar hacia abajo
Page Down
Desplazar al inicio
CTRL + Home
Desplazar hasta el final
CTRL + End
Detalle (Primero, "Ir a Detalle"
Ir a Siguiente pestaña
Ir a Pestaña anterior

Análisis

1 / 758
1.WO/2022/140845NEUTRALIZING MONOCLONAL ANTIBODIES AGAINST COVID-19
WO - 07.07.2022
Clasificación Internacional C07K 16/10
CQUIMICA; METALURGIA
07QUIMICA ORGANICA
KPEPTIDOS
16Inmunoglobulinas, p. ej. anticuerpos mono o policlonales
08contra materiales víricos
10de virus ARN
 Nº de solicitud PCT/CA2021/051873 Solicitante VAL-CHUM, LIMITED PARTNERSHIP Inventor/a STAMATATOS, Leonidas
The present application relates to neutralizing antibodies or antigen-binding fragments thereof against betacoronaviruses such as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), to nucleic acid(s) encoding such neutralizing antibodies or antigen-binding fragments thereof, and to mixture and compositions comprising such antibodies, antigen-binding fragments or nucleic acids. Methods and uses of the antibodies, antigen-binding fragments thereof, nucleic acid(s) or compositions, including therapeutic, diagnostic, and preventative methods and uses for betacoronavirus infections and related diseases such as COVID-19, are also described.
2.WO/2022/165039ANTI-SARS-COV-2 SPIKE GLYCOPROTEIN ANTIBODIES AND THE THERAPEUTIC USE THEREOF
WO - 04.08.2022
Clasificación Internacional C07K 16/10
CQUIMICA; METALURGIA
07QUIMICA ORGANICA
KPEPTIDOS
16Inmunoglobulinas, p. ej. anticuerpos mono o policlonales
08contra materiales víricos
10de virus ARN
 Nº de solicitud PCT/US2022/014103 Solicitante TALEM THERAPEUTICS LLC Inventor/a ROODINK, Ilse
The present application relates to neutralizing antibodies or antigen-binding fragments thereof against betacoronaviruses such as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), to nucleic acid(s) encoding such neutralizing antibodies or antigen-binding fragments thereof, and to mixture and compositions comprising such antibodies, antigen-binding fragments or nucleic acids. Such neutralizing antibodies or antigen-binding fragments thereof are able to block betacoronavirus entry into cells and/or to induce complement-dependent cytotoxicity (CDC), antibody-dependent cellular cytotoxicity (ADCC) and/or antibody-dependent cellular phagocytosis (ADCP) against betacoronavirus-infected cells. Methods and uses of the antibodies, antigen-binding fragments thereof, nucleic acid(s) or compositions, including therapeutic, diagnostic, and preventative methods and uses for betacoronavirus infections and related diseases such as COVID-19, are also described.
3.20210353620Method of treating severe acute respiratory syndrome (SARS) virus infection by administering a protein disulfide isomerase (PDI) inhibitor
US - 18.11.2021
Clasificación Internacional A61K 31/496
ANECESIDADES CORRIENTES DE LA VIDA
61CIENCIAS MEDICAS O VETERINARIAS; HIGIENE
KPREPARACIONES DE USO MEDICO, DENTAL O PARA EL ASEO
31Preparaciones medicinales que contienen ingredientes orgánicos activos
33Compuestos heterocíclicos
395que tienen el nitrógeno como heteroátomo de un ciclo, p. ej. guanetidina o rifamicina
495que tienen ciclos con seis eslabones con dos nitrógenos como únicos heteroátomos de un ciclo, p. ej. piperazina
496Piperazinas no condensadas conteniendo otros heterociclos, p. ej. rifampicina, tiotixeno
 Nº de solicitud 17320069 Solicitante The University of Vermont and State Agricultural College Inventor/a Vikas Anathy

Compositions and methods involving protein disulfide isomerase (PDI) inhibitors, such as protein disulfide isomerase A3 (PDIA3) inhibitory compounds, for human coronavirus, such as severe acute respiratory syndrome (SARS) virus (e.g., SARS-CoV-2), therapies are disclosed herein.

4.3101131COMPOSITIONS AND METHODS FOR PREVENTING AND TREATING CORONAVIRUS INFECTION - SARS­COV-2 VACCINES
CA - 31.07.2021
Clasificación Internacional C12N 15/15
CQUIMICA; METALURGIA
12BIOQUIMICA; CERVEZA; BEBIDAS ALCOHOLICAS; VINO; VINAGRE; MICROBIOLOGIA; ENZIMOLOGIA; TECNICAS DE MUTACION O DE GENETICA
NMICROORGANISMOS O ENZIMAS; COMPOSICIONES QUE LOS CONTIENEN; PROPAGACION, CULTIVO O CONSERVACION DE MICROORGANISMOS; TECNICAS DE MUTACION O DE INGENIERIA GENETICA; MEDIOS DE CULTIVO
15Técnicas de mutación o de ingeniería genética; ADN o ARN relacionado con la ingeniería genética, vectores, p. ej. plásmidos, o su aislamiento, su preparación o su purificación; Utilización de huéspedes para ello
09Tecnología del ADN recombinante
11Fragmentos de ADN o de ARN; sus formas modificadas
12Genes que codifican proteínas animales
15Inhibidores de proteasas, p. ej. antitrombina, antitripsina, hirudina
 Nº de solicitud 3101131 Solicitante JANSSEN PHARMACEUTICALS, INC. Inventor/a LANGEDIJK, JOHANNES PETRUS MARIA
P217625CA00 CR U6043CAN P1- 269 -COMPOSITIONS AND METHODS FOR PREVENTING AND TREATING CORONAVIRUS INFECTION - SARS-COV-2 VACCINESAbstractThe invention relates to immunogenic compositions and vaccines containing a coronavirus(e.g., Wuhan coronavirus (2019-nCoV; also referred to as SARS-CoV-2)) protein or a polynucleotide encoding a coronavirus (e.g., Wuhan coronavirus (2019-nCoV; SARS-CoV-2)) protein and uses thereof. The invention also provides methods of treating and/or preventing a coronavirus (e.g., Wuhan coronavirus (2019-nCoV; SARS-CoV-2)) infectionby administering an immunogenic composition or vaccine to a subject (e.g., a human). Theinvention also provides methods of detecting and/or monitoring a protective anti-coronavirus (e.g., Wuhan coronavirus (2019-nCoV; SARS-CoV-2)) antibody response (e.g., anti-coronavirus antibody response, e.g., anti-2019-nCoV antibody response, e.g., anti-Spike antibody response, e.g., anti-Spike neutralizing antibody response). The presentinvention relates to isolated nucleic and/or recombinant nucleic acid encoding acoronavirus S protein, in particular a SARS-CoV-2 S protein, and to the coronavirus S proteins, as well as to the use of the nucleic acids and/or proteins thereof in vaccines.<1093966>Date Recue/Date Received 2020-11-28
5.WO/2022/228827HUMAN NEUTRALIZING MONOCLONAL ANTIBODIES AGAINST SARS-COV-2 AND USES THEREOF
WO - 03.11.2022
Clasificación Internacional C07K 16/10
CQUIMICA; METALURGIA
07QUIMICA ORGANICA
KPEPTIDOS
16Inmunoglobulinas, p. ej. anticuerpos mono o policlonales
08contra materiales víricos
10de virus ARN
 Nº de solicitud PCT/EP2022/058777 Solicitante INSTITUT PASTEUR Inventor/a MOUQUET, Hugo
The invention relates to antibodies against Severe Acute Respiratory Syndrome-related Coronavirus 2 (SARS-CoV-2), in particular human neutralizing monoclonal antibodies against Severe Acute Respiratory Syndrome-related Coronavirus 2 (SARS-CoV-2) and their use for the diagnosis, monitoring, prevention, and treatment of SARS-CoV-2 infection and associated disease (COVID-19).
6.20230127518IDEBENONE FOR THE TREATMENT OF ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) IN PATIENTS DIAGNOSED WITH A CORONAVIRUS INFECTION
US - 27.04.2023
Clasificación Internacional A61K 31/122
ANECESIDADES CORRIENTES DE LA VIDA
61CIENCIAS MEDICAS O VETERINARIAS; HIGIENE
KPREPARACIONES DE USO MEDICO, DENTAL O PARA EL ASEO
31Preparaciones medicinales que contienen ingredientes orgánicos activos
12Cetonas
122que tienen el átomo de oxígeno unido directamente a un ciclo, p. ej.quinonas, vitamina K1, antralina
 Nº de solicitud 17911781 Solicitante BEMIDO SA Inventor/a Giampiero DE LUCA

The present invention relates to idebenone for treating Acute Respiratory Distress Syndrome (ARDS) associated with a viral infection, particularly a coronavirus infection, such as Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

7.WO/2023/044397ENGINEERED RECEPTORS AND MONOCLONAL ANTIBODIES FOR CORONAVIRUSES AND USES THEREOF
WO - 23.03.2023
Clasificación Internacional A61P 11/00
ANECESIDADES CORRIENTES DE LA VIDA
61CIENCIAS MEDICAS O VETERINARIAS; HIGIENE
PACTIVIDAD TERAPEUTICA ESPECIFICA DE COMPUESTOS QUIMICOS O DE PREPARACIONES MEDICINALES
11Medicamentos para el tratamiento de trastornos del aparato respiratorio
 Nº de solicitud PCT/US2022/076515 Solicitante THE BOARD OF THE TRUSTEES OF THE UNIVERSITY OF ILLINOIS Inventor/a CHAN, Kui K.
This disclosure relates generally to human ACE2 polypeptides that exhibit enhanced binding to the S protein of SARS-CoV-2, or increased affinity, that can be used as therapeutic agents in combination with monoclonal antibodies for the prophylaxis (pre- or post-exposure prophylaxis), or treatment of COVID-19, or disease caused by any coronavirus that utilizes ACE2 as a cellular receptor.
8.WO/2022/060900SHARK-DERIVED BINDING MOLECULES FOR SARS-COV-2 CORONAVIRUS AND USES THEREOF
WO - 24.03.2022
Clasificación Internacional A61K 39/395
ANECESIDADES CORRIENTES DE LA VIDA
61CIENCIAS MEDICAS O VETERINARIAS; HIGIENE
KPREPARACIONES DE USO MEDICO, DENTAL O PARA EL ASEO
39Preparaciones medicinales que contienen antígenos o anticuerpos
395Anticuerpos; Inmunoglobulinas; Inmunosuero, p. ej. suero antilinfocitario
 Nº de solicitud PCT/US2021/050545 Solicitante THE HENRY M. JACKSON FOUNDATION FOR THE ADVANCEMENT OF MILITARY MEDICINE, INC. Inventor/a JOYCE, Michael Gordon
Disclosed herein are shark-derived antibodies and binding molecules with high binding affinity for SARS-CoV-2 coronavirus and the use thereof. Some of the shark-derived antibodies and binding molecules also demonstrate cross-reactivity with and neutralization of other related sarbecoviruses. The complementarity determining region (CDR) sequences and binding characteristics for these antibodies and binding molecules are provided. Also disclosed are the use of these antibodies and binding molecules to detect SARS-CoV-2 coronavirus or other related sarbecoviruses or to prevent or treat SARS-CoV-2 coronavirus or other related sarbecovirus infections.
9.WO/2006/086561NEUTRALIZING MONOCLONAL ANTIBODIES AGAINST SEVERE ACUTE RESPIRATORY SYNDROME-ASSOCIATED CORONAVIRUS
WO - 17.08.2006
Clasificación Internacional A61K 39/00
ANECESIDADES CORRIENTES DE LA VIDA
61CIENCIAS MEDICAS O VETERINARIAS; HIGIENE
KPREPARACIONES DE USO MEDICO, DENTAL O PARA EL ASEO
39Preparaciones medicinales que contienen antígenos o anticuerpos
 Nº de solicitud PCT/US2006/004599 Solicitante NEW YORK BLOOD CENTER Inventor/a JIANG, Shibo
The present invention provides an isolated antibody capable of binding to the receptor- binding domain of the spike protein of the severe acute respiratory syndrome-associated coronavirus (SARS-CoV) so as to competitively inhibit the binding of the SARS-CoV to host cells. These mAbs or substances can be used: 1) as passive-immunizing agents for prevention of SARS-CoV infection; 2) as biological reagents for diagnosis of SARS-CoV infection; 3) as immunotherapeutics for early treatment of SARS-CoV infection; and 4) as probes for studying the immunogenicity, antigenicity, structure, and function of the SARS- CoV S protein.
10.WO/2021/186190CORONAVIRUS ANTIBODY
WO - 23.09.2021
Clasificación Internacional C07K 16/10
CQUIMICA; METALURGIA
07QUIMICA ORGANICA
KPEPTIDOS
16Inmunoglobulinas, p. ej. anticuerpos mono o policlonales
08contra materiales víricos
10de virus ARN
 Nº de solicitud PCT/GB2021/050685 Solicitante IMPERIAL COLLEGE INNOVATIONS LIMITED Inventor/a XU, Xiao-Ning
An antibody or antigen-binding fragment thereof is described which binds to the spike protein S2 domain of severe acute respiratory syndrome coronavirus (SARS-CoV), Middle East respiratory syndrome-related coronavirus (MERS-CoV) and/ or severe acute respiratory syndrome coronavirus 2 (SARS CoV-2). The antibodies can be used in the diagnosis and treatment of coronavirus infection. The invention extends to compositions comprising the antibodies, including pharmaceutical compositions, diagnostic compositions, and kits. The invention also extends to methods of making and using the antibodies, for example in the diagnosis and therapy of coronavirus infections.
# -